Prebiotic and Probiotic Treatment Trial in Multiple Sclerosis
Prebiotic vs. Probiotic Treatment in Multiple Sclerosis (MS) or Clinically Isolated Syndrome (CIS)
Sponsor: NMSS
Enrolling: Male and Female Patients
Study Length: 24 Weeks
Clinic Visits: 5
IRB Number: AAAR9614
U.S. Govt. ID: NCT04038541
Contact: Fatoumata Diallo: 212-305-1485 / mscenter_neuro@cumc.columbia.edu
Additional Study Information: This study will be used to evaluate the immunologic effects of Prebiotics (soluble fiber required by beneficial bacteria), in comparison to Probiotics (beneficial bacteria), in individuals with Multiple Sclerosis (MS) and Clinically Isolated Syndrome (CIS).
This study is closed
Investigator
Rebecca Straus Farber, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
Have you been diagnosed with MS (relapsing type) or CIS? Yes No
Have you been receiving anti-CD20 therapy (rituximab or ocrelizumab)? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Fatoumata Diallo
mscenter_neuro@cumc.columbia.edu
212-305-1485
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE